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ABSTRACT: Anthocyanins (ACNs) are promising health-enhancing phenolic compounds. We focus on ACN animal tissue
bioavailability to provide an evidentiary link between tissue ACNs and their associated health properties. We performed a
systematic review of electronic libraries; 279 results were retrieved, and 13 publications met inclusion criteria. Extracted
information included animal model employed, administration route, doses, analysis method, and ACN concentration values in
tissues. Total ACN concentrations were detected in mice kidney (2.17 × 105 pmol/g), liver (1.73 × 105 pmol/g), heart (3.6 ×
103 pmol/g), and lung (1.16 × 105 pmol/g); and in pig brain (6.08 × 103 pmol/g). ACNs showed a predominance of parent
ACNs in long-term experiments versus an ACN metabolite predominance in short-term experiments. ACNs detected in animal
tissues, such as cyanidin-3-glucoside, suggest it may have an important role in human health. This information could be useful to
determine proper ACN-intake biomarkers in biological samples in futures studies.
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■ INTRODUCTION
In recent years, preventive medicine has acquired a signifi-
cantly more important role in healthcare systems primarily due
to the increase in aged population and the prevalence of
obesity, diabetes, metabolic syndrome, and hypertension1,2
in which a healthy diet and lifestyle play a significant role.3
Dietary changes and healthy eating patterns such as the
Mediterranean diet are characterized by a high intake of fruit,
vegetables, fish, nuts, and olive oil, that can reduce the risk for
chronic noncommunicable diseases.4,5 However, most bio-
active molecules present in fruits and vegetables and the corre-
sponding biochemical pathways that grant them their associated
health benefits are still unclear.
Among the most well-known bioactive molecule groups
found in fruits and vegetables are the phenolic compounds
such as anthocyanins (ACNs). ACNs are water-soluble plant
pigments responsible of giving red and blue coloration in fruits,
flowers, seeds, and plants.6 They are frequently found in the
skin of many fruits and in the flesh of some berries,7 with con-
centrations ranging from 0.1% up to 1.0% of the fruit’s or vege-
table’s dry weight.8 ACNs consist of a wide range of molecule
classes and subclasses,9 each one with its own properties and
most of them capable of modulating or regulating wide and
diverse biochemical pathways.10,11
It is well-known that the ACN’s absorption site12 and the
chemical structure of anthocyanins13 have an impact on the
phenolic profiles that can be detected in human body fluids.
These differences can be attributed to changes in pH between
the gastric and colonic lumens,14,15 but also because of an
important ACN’s metabolization by colonic microbiota which
can occur within the first 2 h after the ingested ACNs reach the
human colon.16 Thus, colonic metabolization often results in
new metabolites that were not present in the original ACN
food source.17−19 These colonic ACN metabolites have shown
interesting potential for human health and could even have
greater biological activity than their parent molecules, since
colonic ACN metabolites are more abundant and are quite
often better absorbed than their ACN parents.20,21 Conse-
quently, ACNs colonic metabolization has a direct impact in
the amount and half-life of different metabolites of ACNs.22
The mentioned differences in ACN absorption and metabo-
lization render different plasmatic phenolic profiles that in turn
may be of paramount importance when determining tissue
profiles and the benefits of long-term versus short-term ACN
ingestion; however, this remains an area of uncertainty. Thus,
absorption and metabolization probably contributes to the
ACN tissue bioavailability, and this might be a key relevant
aspect for determining biomarkers to assess the intake of ACN
containing foods. Moreover, bioavailability of ACNs in tissues
and cells show great potential for the treatment and prevention
of different pathological entities.23−27
In the current Review, we hypothesize on how the ACNs,
either parent ACNs, such as cyanidin-3-glucoside (C3G),
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delphindin-3-glucoside, malvidin-3-glucoside, peonidin-3-glu-
coside (P3G), and petunidin-3-glucoside, or their metabolites
could be detected in target tissues might exert an effect in the
cells in which they are present. In consequence, providing a
link between ACNs present in tissues after their consumption
and the described intracellular mechanisms of action are an
explanation of ACN reported beneficial effects on human
health. We adapted the concept published by de Ferrars et al.13
and defined “parent” ACNs as an ACN structure from which
other molecules, namely, metabolites, are obtained by substi-
tuting or adding radicals through the methylation, conjugation,
sulfation, and glucuronidation. Thus, our primary goal is to
perform a systematic review of the current knowledge reported
on the tissue bioavailability of ACNs in different animal tissues
after the administration of diverse ACN sources and conse-
quently identifying possible bioactive molecules that could be
clinically relevant. Moreover, through an up-to-date descriptive
review of in vitro experiments, we aspire to provide an explana-
tion for the reported in vivo ACN health effects.
■ MATERIALS AND METHODS
Search Strategy and Selection Criteria. For the present Review,
our group adapted the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement (http://www.
prisma-statement.org/), designed for clinical trials,28 to the systematic
review of animal studies due to the lack of a better and more
standardized screening method. An electronic-based search in the
scientific libraries PubMed (http://www.ncbi.nlm.nih.gov/pubmed)
and Scopus (http://www.scopus.com) was performed. A broad search
term of “anthocyanin AND bioavailability” was used for our search,
since more specific options did not render all studies that could meet
the inclusion criteria used for the present Review. Results were
screened based on their titles, abstracts, and full-text availability
according to our inclusion criteria: (1) animal interventions using
ACNs extracts or ACN supplementation and (2) ACNs tissue
bioavailability evaluation. All non-English publications, and studies
that did not report specific metabolite concentration values in tissues
were excluded from the discussion.
Data Extraction, Standardization, and Analysis. Two
independent authors (B.A.S.-R. and Ú.C.) extracted published data
from text and tables; for data published as graphics, approximates
were estimated through scaling; all differences were resolved by a
third reviewer (R.S.). The following information was extracted from
all reviewed studies: (1) study characteristics including the animal
model used, ACN administration routes, doses, and sample analysis
method; and (2) total ACN, parent ACN, or ACN metabolite con-
centration assessed in animal tissues.
All concentration units were converted and homogenized into the
international system of units (molar) using metabolite molecular
weight published in the Phenol-Explorer (http://phenol-explorer.eu/).29
After homogenization, data was analyzed and text, Tables, and Figures
were elaborated, presented, and discussed.
■ RESULTS
Literature Search, Studies Selection, and Character-
istics. A total of 279 results published from inception up to
February 2018 were found in our initial screening. All entries
titles and abstracts were assessed for relevance according to
inclusion criteria; 265 studies did not meet inclusion criteria
and 1 study was excluded because it was not a paper. Thirteen
publications10,11,30−40 were identified and further examined as
full texts. The flow diagram of the selection process used is
shown in Figure 1.
Of all publications evaluated, 7 short-term experiments11,33−37,40
assessed ACN tissue bioavailability after a single dose of ACN
Figure 1. PRISMA statement flowchart for anthocyanin tissue availability adapted to animal studies.
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administered either orally or intravenously (IV). The remaining
6 experiments10,30−32,38,39 assessed ACN tissue bioavailability
after a long-term oral-controlled ACN supplementation. Out of
the 13 studies, 5 were performed on Wistar rats,30,33,35−37 3 on
mice,11,32,34 2 on Sprague−Dawley rats,10,40 2 on pigs,31,38 and
1 on Zucker rats.39
High-performance liquid chromatography and mass spec-
trometry were the most used analysis techniques to determine
ACN concentration in tissues. Kidney, liver, and brain were the
most frequently analyzed organs with highest total ACN
concentrations: 2.17 × 105 pmol/g in mice kidneys,11 1.73 ×
105 pmol/g in mice liver,32 and 6.08 × 103 pmol/g in young
swine brain.38 Complete information on general characteristics
of studies that assessed ACN tissue bioavailability in animals as
well as the total ACN concentrations detected in analyzed
tissues are presented in Table 1.
Short versus Long-Term Tissue ACNs Bioavailability.
One of the differences that was noted through our findings was
that the ACN bioavailability profiles in animal tissues after a
short versus long-term administration of ACNs showed dif-
ferent patterns. We observed a clear predominance of parent
ACNs in long-term experiments, as shown in Table 3, versus
ACNs metabolites predominance in short-term experiments
reflected in Table 2. These differences will be further addressed
and explained in more detail in the following sections.
Tissue Bioavailability in Short-Term Experiments.
In short-term experiments, high methodology variability was
observed. These experiments were performed after a single dose
of an ACN concentrate either orally or IV. Oral doses presented
high variability between 8 mg/kg grape extract37 and 500 mg/kg
C3G extract,11 while IV doses ranged between 1 mg/kg C3G
extract11 and 5 mg/kg bilberry extract.33 Animals were sacrificed
between 0 min and 24 h after administration, although sacrifice
was most commonly performed 15 min after ACN either oral or
IV administration.11,33,35,36
4′-O-methylcyanidin-3-O-β-glucopyranoside highest concen-
tration (19.18 pmol/g) in liver was found 15 min after a 5 mg/kg
IV ACN dose after bilberry extract administration,33 while
in kidneys petunidin-3-glucoside was the highest ACN
(2317.00 pmol/g) found at 15 min after a 670 nmol ACN IV
dose.36 C3G was the parent ACN found at highest concentrations
in brain at 0.25 min (40.46 pmol/g) after the IV administration
of bilberry extract.35 Moreover, C3G was also found in gastro-
intestinal tract (8 × 105 pmol/g), lung (5.19 × 104 pmol/g),
and prostate (4 × 104 pmol/g) with peak concentrations
at different times after an oral single dose of C3G extract.11
Complete information regarding peak concentrations of
parent ACNs and ACN metabolites at different doses and
times from short-term animal interventions are reported in
Table 2.
Tissue Bioavailability in Long-Term Experiments.
High heterogeneity in oral ACN administrated doses was
also noted for long-term interventions: doses ranged from
27.5 mg/kg/day38 up to 617.6 mg/kg/day.32 Animal sacrifices
were performed at different periods comprehended between
10 days and 8 weeks. In long-term experiments, animal brains
were the most common organs analyzed.10,30−32,35,38,41 In the
analyzed brains, the highest concentration for an ACN
was found for malvidin-3-glucoside (4.43 pmol/g) after an
82.5 mg/kg/day oral supplementation with bilberry extract for
3 weeks in young swine pigs.38
Cyanidin-3-rutinoside-5-β-D-glucoside was found in the
heart (1.50 × 10−4 pmol/g), brain (1.85 × 10−4 pmol/g),
liver (3.34 × 10−5 pmol/g), kidney (9.24 × 10−4 pmol/g), and
bladder (2.16 × 10−4 pmol/g) after 2 weeks of 200 mg/kg/day
oral supplementation with bilberry in Wistar rats.30 Complete
information regarding doses, maximum ACN peak or metabo-
lite concentration, and animal organ tissues analyzed for long-
term animal interventions are reported in Table 3.
ACNs Bioavailability in Animal Tissues. Cardiac Tissue
Bioavailability. Out of the 13 studies assessed, 3 studies evalu-
ated the presence of ACNs in animal hearts using different
ACN sources.11,30,32 For mice hearts obtained after a 2 week
ACN 617.6 mg/kg/day oral supplementation with C3G extract,
tissue ACN concentrations were not detected,32 whereas ACN
concentrations of 1.11 pmol/g were reported in heart tissue for
oral ACN doses as low as 200 mg/kg/day in a 3 week inter-
vention using bilberry extract in Wistar rats.30 These differ-
ences in heart ACN detection were probably due to differences
in sample processing proceedings, ACN source, or animal
model used since analysis methods used for ACN detection did
not differ between both studies. Interestingly, higher supple-
mentation oral doses of 2000 mg/kg/day using bilberries in
Wistar rats reported a 54% (0.51 pmol/g) reduction for
heart tissue ACN bioavailability compared with lower doses
(200 mg/kg/day) of bilberry extract,30 suggesting the possible
increase or upregulation in ACN’s degradation and elimination
mechanisms available inside cardiac cells.
In mice hearts, ACNs were also found in short-term
experiments performed when a single C3G extract oral dose of
500 mg/kg was administered to mice, the study reported peak
of C3G (1.4 × 104 pmol/g) 10 min post administration.11
Cyanidin metabolites were the most commonly in animal
hearts analyzed, with the highest concentration reported for
long-term studies was 4.95 × 10−4 pmol/g after administrating
a 200 mg/kg/day oral dose of bilberry for 3 weeks in Wistar
rats,30 and 1.40 × 104 pmol/g on heart for short-term studies
after a single 500 mg/kg oral dose of C3G extract in mice.11
There is no consensus on ACN daily doses and adminis-
tration times that are needed to detect ACNs in target tissues.
However, as stated before, the minimum ACN time and oral
dose supplementation to achieve heart tissue detection has been
demonstrated in rats after 3 weeks of bilberry extract supplemen-
tation with 200 mg/kg/day.30 This oral dose of 200 mg/kg/day in
rats represents a human oral dose of 32.4 mg/kg/day, representing
around 2 g of bilberry extract for a standard 70 kg human.42
Brain Tissue Bioavailability. ACN brain bioavailability was
evaluated in 7 out of the 13 studies that met inclusion criteria
for the present review.10,30−32,35,38,43 ACNs were not detected
in brain tissue after a 48 mg/kg/day oral ACN extract supple-
mentation for an 8 week period with wild blueberry in Sprague−
Dawley rats,10 after 509 mg/kg/day oral dose of blueberry
powder after 10 days in Zucker rats, or after a 617.6 mg/kg/day
oral grape seed extract supplementation for 2 weeks in mice.39
However, a maximum ACN concentration of 6.08 ×
103 pmol/g was found in analyzed brains after a 3 week experi-
ment performed on young swine pigs in which an 82.5 mg/kg/
day oral dose of tart cherry was administered, whereas an ACN
distribution pattern was determined for every brain region.38
In same study, also a direct correlation between dose consumed
and tissue bioavailability was observed.38
In the brain, after an 82.5 mg/kg/day ACN oral dose of tart
cherry, petunidin-3-glucoside was the ACN found in highest
concentration (6.66 pmol/g), followed by malvidin-3-gluco-
side (4.43 pmol/g) and P3G (4.40 pmol/g).38 Moreover, in
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brain, a P3G peak concentration of 2.07 pmol/g was found
after 2 min for a single 8 mg/kg oral raspberry dose.37
Liver Tissue Bioavailability. Total ACN concentrations
were reported in liver, ranging from not detected in Sprague−
Dawley rats after an 8 week period of oral intervention of
48 mg/kg/day with wild blueberry extract,10 to a detected con-
centration of 1.73 × 105 pmol/g in mice livers after a 2 week
oral intervention with 617.6 mg/kg/day of bilberry extract.32
In short-term studies, 4′-O-methyl cyanidin 3-O-β-D-glucopyr-
anoside was the ACN metabolite found in highest concen-
tration (19.18 pmol/g), 15 min after a 5 mg/kg IV dose of
bilberry extract in Wistar rats.33 In long-term experiments,
cyanidin-3-rutinoside-5-β-D-glucoside was the ACN metabolite
found in highest concentrations (1.16 × 10−3 pmol/g), after a
2000 mg/kg/day oral dose for 3 weeks of tart cherry extract in
Wistar rats.30
Kidney Tissue Bioavailability. ACN concentrations detected
in kidney ranged from 1.65 pmol/g after an oral supplemen-
tation of 2000 mg/kg/day with bilberry for 3 weeks,30 up
to 2.17 × 105 pmol/g for a C3G extract unique oral dose of
500 mg/kg presenting a maximal C3G concentration at 10 min
after oral administration in rats.11 In kidney a maximal C3G
concentration was found at 10 min after a unique oral C3G
extract administration,11 while after a single oral dose of
500 mg/kg of raspberry other ACN metabolites such as malvidin-
3-glucoside, P3G, and petunidin-3-glucoside maximum peaks
were detected at 10, 10, and 15 min, respectively.37
Lung Tissue Bioavailability. In lung tissue, C3G was
found at a peak concentration of 3.86 × 105 pmol/g after a
single 5 mg/kg C3G extract IV administrated dose in mice;11
and at a concentration of 1.15 × 104 pmol/g after an oral
supplementation with 617.6 mg/kg of a C3G extract for
2 weeks in mice.32 Beyond C3G, other parent ACNs such as
delphinidin-3-glucoside (3.40 × 104 pmol/g) and P3G (8.80 ×
104 pmol/g) were also found in lungs after oral doses of
617.6 mg/kg of supplementation with a C3G extract for
2 weeks in mice.32
ACN Bioavailability in Other Animal Tissues. ACNs were
also detected in prostatic tissue of mice (total concentrations
of 4.96 × 104 pmol/g), after a single oral 500 mg/kg dose of
C3G extract,11 and on testes of mice (1.16 × 105 pmol/g) after
a 2 week intervention using a dose of 617.6 mg/kg/day of
bilberry oral supplementation.32 However, to date not enough
bioavailability assays have been published regarding ACN
presence in these tissues to properly determine the importance
of specific phenolic compounds in relation of the health of
these organs.
■ DISCUSSION
The present work aims to summarize the knowledge reported
on the ACN’s tissue bioavailability after the administration of
different ACN sources in animals. Thus, identifying possible
bioactive molecules in animal tissues could suggest clinical
relevance for humans. Surprisingly, there is a remarkable lack
of studies that describe both ACN tissue bioavailability and
their pharmacodynamics explaining ACN effects. In order to
solve this issue, we describe the relationship between the ACNs
detected concentrations in animal tissues and their possible
health effects, by providing a link between the findings of ACNs
in in vivo animal assays and in vitro experiments, leading to
determine specific mechanisms of action in cell or/and tissues.
This allowed us to provide a potential explanation of ACN’s
health effects in humans.T
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Tissue ACN Profile Differences in Short versus Long-
Term in Animal Oral Interventions. From current data, we
suggest that the difference in tissue ACN bioavailability profiles
obtained after short and long-term oral assays performed in
animal interventions could be explained by the saturation of
the absorption mechanisms, mainly at gastric level via bili-
translocase, and by the further colonic metabolization of non-
absorbed ACNs after an oral consumption.10 Gastric absorp-
tion is then followed by hepatic metabolization in which ACN
metabolites are created by glucosidation, methylation, and
glucuronidation, and then liberated into the plasma, causing a
rise of ACN metabolite forms that are further delivered to the
different tissues.17
Furthermore, from our results, in oral short-term experi-
ments, a predominance of parent ACNs in tissues is detected,
whereas the long-term oral administration of ACNs can cause
the saturation of the ACN gastric absorption mechanisms,
mainly bilitranslocase located in the mucosecretory and parietal
cells of the stomach.44 This saturation leads to the hydrolysis
of parent ACNs into their metabolites. As a result, total ACN
metabolite concentration increases in the stomach, following
later stages of the digestion process when ACNs are suscep-
tible to be metabolized by colonic microbiota.12,17 Therefore,
in long-term ACN administration, colonic microbiota reconvert
ACNs into their metabolized versions, that are then absorbed
through the colonic epithelia, transferred to the bloodstream,
and from there distributed to the rest of tissues in animals.17
This colonic process is also probably the same for humans.
Whereas in short-term exposure, the main absorption is per-
formed through the gastric epithelia.22,44
A good example of how ACN gut microbiota metabolization
and colonic absorption are relevant to their bioavailability is
the generation of the two major molecules product of C3Gʼs
degradation: protocatechuic acid (PCA) and pholoroglucinal-
dehyde (PGA). After C3G’s ingestion and gastric absorption,
C3G’s remnant concentrations arrive at the colon, where gut
microbiota start its degradation yielding PCA out of C3G’s
B-ring and PGA out of its A-ring.11,22 Afterward, these mole-
cules are absorbed, giving rise to their respective plasmatic
concentration peaks and therefore rending maximum concen-
tration times (T-max; 3.3 ± 0.7 h for PGA and 2.8 ± 1.1 h for
PCA), much later than their parent C3G (1.8 ± 0.2 h).13 This
information suggests that the observed time/dose response over
tissue ACN profiles might be of relevance for tissue-specific
health effects derived from ACN administration. As conse-
quence, the result is that short-term oral exposure to ACNs
leads to a higher presence of parent ACNs, while the long-term
administration renders a more diverse pattern in which ACN
metabolites are more commonly found.
ACN’s Mechanisms of Action and Possible Health
Repercussions. Since ACN mechanisms of action in humans
cannot be determined due to the intrinsic methodologic limita-
tions and ethical concerns to detect their presence in human
tissues, this subject has not yet been properly studied. Because
of that, complementary to animal studies, in vitro studies per-
formed on cellular models become relevant when determining
important bioactive ACN molecules and their effects on
biochemical pathways involved in the treatment or prevention
of a series of pathologies.45−48 ACNs have shown great poten-
tial in cellular models of experimentation as bioactive molec-
ules capable of not just reducing oxidative stress,49−51 but also
possibly being capable of modifying pathways from different
types of cancer (hepatocarcinoma,52 colorectal cancer,53,54 and
breast cancer55,56) or modulating obesity and its associated
low-grade inflammation state.57
ACNs and Cardiac Health. Cardioprotective effects of
some ACNs such as C3G have been demonstrated in mice,
both in cellular and in animal model experiments,58 since it has
been shown to be able to reduce doxorrubicinʼs, an anticancer
drug, cardiotoxicity in myocytes; where after high doses of pure
C3G extract, cellular death was reduced after a 3 week oral supple-
mentation.58 Another study evaluated on an isoproterenol-
induced myocardial infarction mice model, after 28 days of
ACN oral administration. In this study, mice showed reduced
plasmatic protein levels of creatine kinase muscle/brain (CK-MB),
a cardiac necrosis biomarker, increased levels of intracellular
enzymatic antioxidants, and decreased levels of apoptotic markers
probably achieving C3G’s effects through the activation of β1
adrenergic receptors in cardiac cells,23 which in turn could reduce
cytochrome c intracellular concentrations, therefore leading to
fewer cardiac cellular damage and apoptosis.59
Moreover, after 4 weeks of 10 mg/kg/day C3G oral supple-
mentation in rats with myocardial infarction, left ventricle
dilatation and body mass loss were prevented while not showing
any improvements in cardiac structure and function.58 These
cardioprotective effects of C3G were not observed after
8 weeks of ACN administration of the same doses.60 The dis-
crepancy the results obtained after 4 and 8 weeks of daily C3G
consumption need to be addressed.
However, ACN metabolization in the heart might be
generated to counteract possible adverse effects of ACN
activity, since high concentrations of phenolic compounds can
cause rather negative intracellular effects, the opposite of what
has been demonstrated for lower ACN concentrations as
reported before.61
Up to the date of the present Review, few studies have
evaluated the effect of oral ACNs in humans and showed a
lower systolic blood pressure, lower plasmatic triglyceride
(TG) levels, and healthier TG/HDL cholesterol ratio.6,62−64
No experimental studies assessing protective effects of ACN
supplementation after myocardial infarction or heart failure in
humans have been performed.
ACNs and Brain Health. In brain, it has been demon-
strated that ACNs are able to cross the blood-brain barrier;65
however, to the best of our knowledge, the exact mechanism
by which it happens is still unclear.
In animal models, ACN natural dietary supplementation
not only reduced oxidative stress but also neurodegeneration
and memory impairment for a mice model of Alzheimer’s
disease, which could be explained by the regulation of the
phosphorylated-phosphatidylinositol 3-kinase-Akt-glycogen
synthase kinase 3 beta (p-Pl3k/Akt/GSK3β) pathway.27 The
p-Pl3k/Akt/GSK3β reduced reactive oxygen species elevations,
further preventing apoptosis, neurodegeneration,27 and glial
cell death induced by H2O2, as a consequence delaying the age-
related degenerative changes in brain cells.66 Some ACN’s
possible mechanisms of action have been described in in vitro
experiments were the improvement of free radical scavenging,
reactive carbonyl trapping, antiglycation, anti-amyloid β (Aβ)
fibrillation, and microglial neuroprotective effects in murine
cell cultures,50 and in the human neuroblastoma cell line
SK-N-SH.24
The effects of ACNs on brain tissue were observed at oral
doses as low as 15 mg/kg/day in mice,67 which represents a
human equivalent of 1.3 mg/kg/day (91 mg/day for a 70 kg
average person).42 The ACN brain effects could be enhanced
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by the use of nanovehicles by loading polyethylene glycol-gold
nanoparticles with ACNs to increase brain bioavailability.67
As result, ACN exerts an enhanced cellular protection against
Aβ induced oxidative stress involved in Alzheimer’s diseases.68
The nanoparticle delivery system could be a good strategy to
increase intracellular concentrations of ACNs in other tissues.
Moreover, ACN antioxidant protective effects could provide
beneficial effects not only in Alzheimer’s disease, but also in
other neurodegenerative diseases such as Huntington’s demon-
strated in mice where supplementation with ACNs for 3 weeks
showed an improvement in motor functions,69,70 and Parkinson’s
disease where ACNs acted mainly by their free radical scavenging
properties.71 Thus, the demonstrated ACN effects support their
potential for the treatment and prevention of neurodegenerative
diseases.
ACNs hold various pharmacokinetic and pharmacodynamics
profiles due to their structural differences, as demonstrated
with models that used C-labeled ACN molecules that evi-
denced their specific properties. In humans, after a 500 mg
bolus dose of isotopically labeled C3G, maximum plasmatic
concentrations ranged between 10 and 2000 nM and T-max
values comprehended between 2 and 20 h.13 In accordance
with these findings, we suggest that sustained consumption and
ACN source could be of importance when analyzing their
profiles present in the tissues.
ACNs and Hepatic Health. There is a considerable amount
of published evidence about the presence of ACNs on hepatic
tissue, surely because its paramount role in ACN metabo-
lization,11,13,22 and its central role in the degradation and excre-
tion of many molecules. Evidence indicates that ACNs could
help reduce liver inflammation demonstrated by the lower
activity of alanine aminotransferase and aspartate amino-
transferase, two key hepatic inflammation biomarkers, reported
in a murine model of hepatic damage induced by IV injected
lipopolysaccharide and Propionibacterium acnes, in which a
positive reduction of inflammation was observed after the
intake of 50−150 mg/kg/day bilberry extract for 7 days.72
However, there is a remarkable lack of studies that assess the
impact of specific ACN presence in the liver as to prevent
hepatic diseases.
ACNs and Renal Health. The evidence that suggests that
the presence of malvidin-3-glucoside, P3G, and petunidin-3-
glucoside in renal tissue prevented and delayed the progression
not only of renal disease against cisplatin-induced acute kidney
injury that is produced after its use as an anticancer treat-
ment,73 but also of ischemia-reperfusion injury as demonstrated
in mice.74 In consequence, these results suggest a potential aid in
preventing and delaying the progression of acute kidney injury in
humans. On the other hand, ACNs have shown nonspecifically
inhibition properties against the connective tissue growth
factor’s expression, also known as CCN2. This growth factor
has been identified as an important molecule in the development
of kidney failure in diabetic nephropathy, through the retardation
of tumor growth factor-β signaling pathway.75 ACN supple-
mentation with doses as low as 10 mg/kg every 2 weeks for
4 doses in humans retarded glomerular angiogenesis and inhibited
endothelial tube formation promoted by high glucose-exposed
mesangial conditioned media.75
We suggest that ACN source is of importance when ana-
lyzing different polyphenol profiles in different animal tissues;
therefore, not all ACN sources could provide the same health
benefits for humans. Despite the promising effects of ACN on
kidney protection, up to date no human studies regarding the
applications of ACN therapy in kidney disease or glomerular
injuries have been described.
Health Implications of ACNs in Lung and Other
Tissues. ACNs have shown anti-lung-cancer properties as
supported by the results from ACNs’ successful inhibition of
lung cancer cell migration and invasion by suppressing matrix
metalloproteinase (MMP)-2 and MMP-9, as well as different
proteins related to in cancer proliferation, adhesion, and angio-
genesis involved in lung cancer development.76 These
anticancer benefits might be specifically provided by P3G, an
ACN which has demonstrated to inhibit the invasion, motility,
and secretion of MMPs such as MMP-2, MMP-9, and urokinase-
type plasminogen activator in lung cancer cells, by inhibiting
extracellular signal-regulated kinase (ERK)-1/2, a mitogen-
activated protein kinase (MAPK) family member involved in
the regulation of MMP molecules as demonstrated in a lung
cancer cell in vitro model.77 Furthermore, so-called suboptimal
in vitro concentrations of a combination of ACNs have
demonstrated to act synergistically inhibiting the growth of
aggressive non-small-cell lung cancer cells, possibly by their
inhibitory effects on molecules like β-catenin, cyclin B1, and
MMP-9 as well as the inhibition of TNFα-induced nuclear
factor-kappa B (NF-κB) activation.78
Delphinidin is another ACN that has shown anticancer
properties. It is capable of inducing cell apoptosis in lung
cancer cells by inhibiting the epidermal growth factor receptor
(EGFR)/vascular endothelial growth factor receptor 2 (VEGFR2)
pathway,79 and through the suppression of hypoxia-inducible
factor 1-alpha (HIF-1α).80 However, up to date, studies per-
formed on humans have not shown lung cancer preventive
benefits, as is the case of the Kuopio Ischemic Heart Disease
Risk Factor Study, an ongoing prospective study performed in
2682 middle-aged men from Finland, in which a nonsignificant
lung cancer risk reduction of 20% for men was found when
comparing the highest and lowest ACN consumption quartiles.81
One other relevant area of interest that has not been
addressed in this Review is the importance of ACNs in the gas-
trointestinal tract for the prevention of colorectal cancer,53,54
mainly due to the shortage of studies that provide evidence of a
complete ACN profile in gastrointestinal tissues. Nonetheless,
reports of total ACN concentration values of 8.1 μg/g82 or
4.48 × 105 pmol/g11 of intestinal mucosa were described in
mice. Moreover, evidence exists regarding the ability of ACNs
to inhibit intestinal tumor development in ApcMin mice and
growth of human colon cancer cell lines,83,84 and to induce
cytotoxicity and decrease viability of Caco-2 cells, facts that
could hinder the growth of tumoral cells in vivo.85 These studies
demonstrate the presence of ACNs in colorectal tissues and ACN
capability for colon cancer prevention. Though, the lack of more
studies in animals and human populations make difficult the
correlation of ACN consumption and colorectal cancer prevention.
Limitations of the Review. One of the greatest limita-
tions on performing our review was the heterogeneity between
the study methodologies, regarding the animal models
employed, doses used, experiment duration, ACN sources
and profiles, which could hinder the direct comparisons
between studies. Another limitation observed was that ACN
source composition was rarely described in published articles,
making difficult to determine the molecular origin of the ACN
profiles demonstrated, which is of paramount importance to
differentiate the possible best ACN sources for specific tissues
or health effects or pathologies. Published studies were found
to be either focused on the metabolism, bioavailability, or
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health effects, but there are no studies that integrate this infor-
mation altogether. As a consequence, under these conditions,
it is not easy to determine which parent or ACN metabolite is
actually responsible for observed health effects in in vivo
studies.
Final Remarks. The presence of parent or ACN metabo-
lites in animal tissues could explain the myriad of health
benefits attributed to oral or IV administration of ACNs. C3G
and its metabolites are one of the most frequently found
metabolites in tissues. ACN source, dose, and consumption
time are of paramount importance when analyzing ACN profiles
in target tissues.
From the analyzed information obtained through this
Review, we suggest that C3G, present in target tissues, could
have an interesting potential for the reduction of myocardial
infarction negative tissue effects and neurodegenerative
diseases such as Alzheimer’s and Parkinson’s, and could also
help delay or even reverse acute renal failure. Therefore, the
published evidence indicates that the ACNs detected in animal
tissues, such as C3G, may have an important role and could be
one of the most promising bioactive molecules for human
health. Moreover, this information could be useful to deter-
mine proper ACN-intake biomarkers in biological samples in
futures studies.
■ AUTHOR INFORMATION
Corresponding Author
*Tel: (+34) 977 75 93 75. E-mail: ursula.catalan@urv.cat.
ORCID
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Acquisition of data: B.A.S-R. and Ú.C. Analysis and
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